Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in active rheumatoid arthritis (SUNDIAL)
NCT00443651Phase 3Completed
- Sponsor
- Genentech
- Start
- Jan 2007
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, open-label trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Genentech. Primary endpoint: Percentage of Patients Developing a Serious Adverse Event Within 24 Weeks. Started Jan 2007; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00443651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00443651.